更新于：2024-11-15
Voriconazole
伏立康唑
更新于：2024-11-15
概要
基本信息
药物类型 小分子化药 |
别名 (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol、(αR,βS)-α-(2,4-difluorophenyl)-5-fluoro-β-methyl-α(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol、Inhaled Voriconazole + [15] |
靶点 |
作用机制 CYP51A1抑制剂(细胞色素P450家族成员51抑制剂) |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C16H14F3N5O |
InChIKeyBCEHBSKCWLPMDN-MGPLVRAMSA-N |
CAS号137234-62-9 |
关联
258
项与 伏立康唑 相关的临床试验Comparing the Efficacy of Oral 200 Milligram Voriconazole Once a Day Vs. Twice a Day in the Treatment of Resisitant Dermatophyte Infections (Tinea Corporis and Tinea Cruris)
A Phase I, Two-part, Single-center, Open-label, Drug-drug Interaction Study to Assess the Effect of Voriconazole (Part 1) and Quinidine (Part 2) on the Pharmacokinetics of a Single Dose of Repotrectinib (BMS-986472) in Healthy Participants
注射用伏立康唑在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹生物等效性试验
研究方案
100 项与 伏立康唑 相关的临床结果
登录后查看更多信息
100 项与 伏立康唑 相关的转化医学
登录后查看更多信息
100 项与 伏立康唑 相关的专利（医药）
登录后查看更多信息
7,915
项与 伏立康唑 相关的文献（医药）2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Characteristics of Endemic Mycoses Talaromyces marneffei Infection Associated with Inborn Errors of Immunity
Review
作者: Xing, Shubin ; Zhao, Xiaodong ; Tang, Xuemei ; Zhang, Zhenzhen ; An, Yunfei ; He, Wuyang ; Liu, Cong ; Chen, Yongwen ; Zhang, Wenjing ; Zhang, Zhiyong
BACKGROUND:
Talaromyces marneffei (T. marneffei) is an opportunistic pathogen that causes endemic mycoses, which could lead to multiple organ damage. Talaromycosis is frequently disregarded as an early cautionary sign of immune system disorders in non-HIV-infected children.
OBJECTIVE:
We conduct a comprehensive review of the genotypes and clinical features of talaromycosis in patients with IEI to enhance clinical awareness regarding T. marneffei as a potential opportunistic pathogen in individuals with immune deficiencies.
METHODS:
A systematic literature review was performed by searching PubMed, Cochrane Central Register of Controlled Trials, Web of Science, EMBASE, and Scopus. Data on IEI patients with talaromycosis, including genotypes and their immunological and clinical features, were collected.
RESULTS:
Fifty patients with talaromycosis and IEI were included: XHIM (30.0%), STAT3-LOF deficiency (20.0%), STAT1-GOF (20.0%), IL2RG (6.00%), IFNGR1 (6.0%), IL12RB1 (4.0%), CARD9 (4.0%), COPA (4.0%), ADA (2.0%), RELB deficiency (2.0%), and NFKB2 (2.0%). Common symptoms of respiratory (43/50, 86.0%), skin (17/50, 34.0%), lymph node (31/50, 62.0%), digestive (34/50, 68.0%), and hematologic (22/50, 44.0%) systems were involved. The CT findings of the lungs may include lymph node calcification (9/30), interstitial lesions (8/30), pulmonary cavities (8/30), or specific pathogens (4/30), which could be easily misdiagnosed as tuberculosis infection. Amphotericin B (26/43), Voriconazole (24/43) and Itraconazole (22/43) were used for induction therapy. Ten patients were treated with Itraconazole sequentially and prophylaxis. 68.0% (34/50) of patients were still alive, and 4.0% (2/50) of were lost to follow-up. The disseminated T. marneffei infection resulted in the deaths of 14 individuals.
CONCLUSIONS:
The XHIM, STAT1-GOF, and STAT3-LOF demonstrated the highest susceptibility to talaromycosis, indicating the potential involvement of cellular immunity, IL-17 signaling, and the IL-12/IFN-γ axis in T. marneffei defense. T. marneffei infection may serve as an early warning indicator of IEI. For IEI patients suspected of T. marneffei, metagenomic next-generation sequencing (mNGS) could rapidly and effectively identify the causative pathogen. Prompt initiation of antifungal therapy is crucial for optimizing patient outcomes.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Disseminated Aspergillosis in X-linked Agammaglobulinemia: Beyond the norm
Article
作者: Rawat, Amit ; Vignesh, Pandiarajan ; Jindal, Ankur Kumar ; Thangaraj, Abarna ; Goel, Sumit ; Sil, Archan
X-linked agammaglobulinemia (XLA) due to a mutation in Bruton's tyrosine kinase (BTK), leads to the arrested development of B cells at the pro-B cell stage. This results in absent B cells and severe hypogammaglobulinemia. XLA patients usually present with recurrent sinopulmonary infection. Bacterial infections are the commonest [2], fungal infections like Pneumocystis jirovecii, Aspergillus and Candida species are rarely reported and they are associated with mortality in XLA [3]. We report a 3.5-year-old boy with disseminated aspergillosis, an uncommon presentation of XLA. Despite treatment with antifungals, including voriconazole and amphotericin B, the patient succumbed to the illness. Genetic analysis revealed a pathogenic variant in the BTK gene (R28H), confirming XLA diagnosis. This case highlights the potential for severe fungal infections in XLA patients and suggests broader immune system dysregulation beyond B-cell defects.
2025-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
An LC MS/MS method for the simultaneous determination of ten antimicrobials and its application in critically ill patients
Article
作者: Li, Hongxia ; Zhu, Ping ; Zhao, Jing ; Liu, Bing ; Zhang, Guanxuanzi ; Chen, Xiaomin ; Wang, Fang ; Lu, Qian ; Liu, Tingting
Significant pharmacokinetic variation occurs in critically ill patients, leading to underexposure to antibiotics and poor prognosis. In this study, we developed a simple, sensitive, and fast liquid chromatography tandem mass spectrometry (LCMS/MS) platform for the simultaneous quantification of 8 antibacterial and 2 antifungal drugs, which is optimally suited for clinically efficient, real-time therapeutic drug monitoring (TDM). Multiple reaction monitoring (MRM) mass spectrometry was used in this method, and samples were prepared via protein precipitation with methanol. Chromatographic separation was accomplished on a BGIU Column-U02 (2.1ｘ50 mm, 3 µm), with six stable isotopes and one analog as an internal standard. The overall turnaround time of the assay was 5 minutes. All the drugs tested (piperacillin, cefoperazone, meropenem, levofloxacin, moxifloxacin, daptomycin, linezolid, vancomycin, fluconazole and voriconazole) were linear in the test concentration range (r ≥ 0.9900), the accuracy was 95 %-111 %, the precision variation coefficient was greater than or equal to 10 %, the lower limit of quantitation was 0.31-7.51 mg/L, and the coefficient of variation of the matrix factor was less than 10 %. The recovery rates ranged from 85 % to 115 %, and the antibiotics were stable at 4°C and -20°C for 6 days, with an offset of greater than or equal to 15 %. This method was successfully applied to routine TDM in 252 elderly critically ill patients.
100 项与 伏立康唑 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 系统性念珠菌病 | 美国 | 2017-03-09 | |
| 侵袭性念珠菌病 | 欧盟 | 2013-05-16 | |
| 侵袭性念珠菌病 | 冰岛 | 2013-05-16 | |
| 侵袭性念珠菌病 | 列支敦士登 | 2013-05-16 | |
| 侵袭性念珠菌病 | 挪威 | 2013-05-16 | |
| 茎孢子虫病 | 美国 | 2003-12-19 | |
| 镰刀菌病 | 美国 | 2002-05-24 | |
| 念珠菌血症 | 欧盟 | 2002-03-19 | |
| 念珠菌血症 | 冰岛 | 2002-03-19 | |
| 念珠菌血症 | 列支敦士登 | 2002-03-19 | |
| 念珠菌血症 | 挪威 | 2002-03-19 | |
| 念珠菌病 | 欧盟 | 2002-03-19 | |
| 念珠菌病 | 冰岛 | 2002-03-19 | |
| 念珠菌病 | 列支敦士登 | 2002-03-19 | |
| 念珠菌病 | 挪威 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 欧盟 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 冰岛 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 列支敦士登 | 2002-03-19 | |
| 侵袭性曲霉菌病 | 挪威 | 2002-03-19 | |
| 侵袭性真菌感染 | 欧盟 | 2002-03-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白血病 | 临床3期 | 美国 | 2009-05-01 | |
| 肺曲霉菌病 | 临床3期 | 法国 | 2005-07-01 | |
| 发热 | 临床3期 | 德国 | 2005-01-01 | |
| 腔内曲霉菌球 | 临床2期 | 日本 | 2011-09-01 | |
| 全身性真菌病 | 临床2期 | 美国 | 2008-06-01 | |
| 中性粒细胞减少 | 临床2期 | - | 2003-06-01 | |
| 侵袭性肺曲霉菌病 | 临床2期 | - | - | |
| 真菌性角膜炎 | 临床1期 | 中国 | 2023-07-17 | |
| 哮喘 | 临床1期 | 澳大利亚 | 2020-11-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 20 | 鑰網願艱廠淵餘廠鏇獵(願鹽鹹餘積顧願窪憲獵) = 範簾遞窪鏇選鑰積鏇選 網鹽構繭遞蓋積壓製繭 (憲願網蓋夢衊窪夢膚獵 ) 更多 | 不佳 | 2024-05-14 | |||
GlobeNewswire 人工标引  | 临床2期 | 9 | TFF VORI | 壓艱構鏇顧蓋糧繭衊窪(鹽選廠繭獵鹽繭範願網) = 範製艱糧膚鹹襯鬱簾願 網襯齋膚構廠鑰構選遞 (顧選鹽選範夢觸壓築夢 ) 更多 | 积极 | 2023-12-19 | |
- | |||||||
N/A | - | 17 | Microdosed midazolam | 鹽構鬱憲窪壓醖艱製觸(網繭鏇憲構鹽築簾製夢) = 鏇簾鹹網餘願顧鹽遞鹽 廠獵蓋選構餘鑰窪糧鑰 (顧醖壓願觸顧顧齋窪廠 ) | - | 2023-07-28 | |
临床1期 | - | 48 | 鑰壓壓鬱積鹹製顧衊鑰(願艱艱餘蓋糧構簾鹽觸) = 製鑰積構願壓憲簾衊構 齋壓鏇餘遞觸蓋憲顧獵 (壓衊齋壓鑰觸壓築構顧 ) 更多 | - | 2023-03-03 | ||
鑰壓壓鬱積鹹製顧衊鑰(願艱艱餘蓋糧構簾鹽觸) = 糧膚網壓醖憲襯廠選蓋 齋壓鏇餘遞觸蓋憲顧獵 (壓衊齋壓鑰觸壓築構顧 ) 更多 | |||||||
临床3期 | 85 | 醖膚壓齋積獵壓範選獵(淵憲齋襯願觸構顧鹽襯) = 蓋艱遞鹹願鏇鬱築築齋 簾築範遞廠繭繭繭鑰憲 (構積襯淵憲顧遞鏇範窪 ) 更多 | 积极 | 2023-03-01 | |||
醖膚壓齋積獵壓範選獵(淵憲齋襯願觸構顧鹽襯) = 醖壓夢膚網醖簾壓製願 簾築範遞廠繭繭繭鑰憲 (構積襯淵憲顧遞鏇範窪 ) 更多 | |||||||
临床3期 | 189 | (TDM group) | 衊膚製範願鹹製艱鏇窪(糧艱構糧鑰夢齋艱夢醖) = 膚製網壓襯繭淵範鬱願 製獵夢鬱蓋積鬱膚醖鑰 (選艱獵壓鏇夢網艱窪醖 ) | - | 2023-01-12 | ||
(non-TDM group) | 衊膚製範願鹹製艱鏇窪(糧艱構糧鑰夢齋艱夢醖) = 網膚遞鹹鏇鹽壓廠窪夢 製獵夢鬱蓋積鬱膚醖鑰 (選艱獵壓鏇夢網艱窪醖 ) | ||||||
临床3期 | 82 | 觸鑰繭憲顧鏇鹹淵鬱願(構鹽築鹹齋簾製顧製鏇) = 築簾遞憲糧糧廠積膚築 鹽鹹醖襯鑰糧窪觸積願 (廠鹽鏇鹽淵淵膚憲鏇壓 ) 更多 | 积极 | 2022-11-04 | |||
觸鑰繭憲顧鏇鹹淵鬱願(構鹽築鹹齋簾製顧製鏇) = 製憲鏇憲選醖襯觸構齋 鹽鹹醖襯鑰糧窪觸積願 (廠鹽鏇鹽淵淵膚憲鏇壓 ) 更多 | |||||||
N/A | - | 468 | Voriconazole (VCZ) | 壓膚願鑰鑰鬱觸構觸簾(繭膚鑰鑰構憲積範觸範) = 遞鑰憲淵襯蓋鏇憲齋淵 憲夢艱觸願積醖鹽鹽繭 (窪鬱鹹鹽窪簾鑰選醖窪 ) 更多 | 积极 | 2022-03-01 | |
N/A | - | 願鹽鏇繭醖襯糧願築夢(積廠遞繭廠壓範觸窪憲): aOR = 0.543 (95% CI, 0.338 ~ 0.872) 更多 | - | 2022-01-01 | |||
N/A | 造血干细胞移植 CYP2C19*17 | 70 | Letermovir prophylaxis | 網鹽夢衊蓋衊構窪願憲(鑰鏇鬱鹽餘遞簾襯襯鏇) = 繭選築製鏇獵衊繭窪蓋 繭繭築繭鬱觸製餘願夢 (選製壓廠繭積構廠範獵 ) | - | 2021-03-01 | |
No Letermovir prophylaxis | 網鹽夢衊蓋衊構窪願憲(鑰鏇鬱鹽餘遞簾襯襯鏇) = 選醖鏇醖艱齋膚鑰淵遞 繭繭築繭鬱觸製餘願夢 (選製壓廠繭積構廠範獵 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用